Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2006-08-29Clinical Trial Update: Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder [Phase 3]
A Phase 3 open-label trial investigating atomoxetine's impact on academic outcomes in children aged 8-11 with ADHD has completed.
-
FDA label_change · 2006-08-24FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
FDA approves a supplemental application for FOCALIN (dexmethylphenidate hydrochloride) from Sandoz Inc, resulting in changes to the drug's l…
-
FDA approval · 2006-08-10FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
The FDA approved a supplemental application for METHYLIN (methylphenidate hydrochloride) from Shionogi, resulting in labeling updates.
-
FDA approval · 2006-08-10FDA Approved: DEXEDRINE SPANSULE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Dexedrine Spansule (dextroamphetamine sulfate) submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2006-08-08FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate from Sandoz Inc, updating an already approved product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2006-08-08FDA Approved: RITALIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Ritalin (methylphenidate hydrochloride) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2006-08-01FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) from Sandoz Inc.
-
FDA approval · 2006-07-27FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the Methylphenidate Transdermal System filed by PADAGIS US LLC.
-
FDA approval · 2006-07-26FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for a product containing dextroamphetamine saccharate, amphetamine aspartat…
-
CLINICAL_TRIALS trial_result · 2006-07-24Clinical Trial Update: A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder [Phase 4]
Phase 4 functional outcomes study comparing atomoxetine-hydrochloride to placebo in adults with Attention-Deficit/Hyperactivity Disorder has…
-
CLINICAL_TRIALS trial_result · 2006-07-07Clinical Trial Update: Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents [Phase 4]
Phase 4 trial update evaluating the effect of atomoxetine on ADHD-related insomnia in children and adolescents. The study status is currentl…
-
FDA approval · 2006-06-16FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA granted a supplemental approval to Prasco Laboratories for a mixed amphetamine salts product containing dextroamphetamine and amphetamin…